

Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa

September 30 2011

In a paper published in the October 2011 issue of *Experimental Biology and Medicine*, a team of researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have achieved temporary functional preservation of photoreceptors in a mouse model for retinitis pigmentosa (RP) using novel bipartite gene therapy.

RP is a heterogeneous disorder characterized by <u>progressive</u> <u>degeneration</u> of rod photoreceptors (which mediate night vision) causing night blindness and eventually total blindness. About 36,000 cases of simplex and familial RP worldwide are caused by mutant phosphodiesterase (PDE6). Says Dr. Tsang,

"Victor McKusick's Mendelian Inheritance in Man catalog has approximately 4,000 genetic disease entries, but only 4 of these are already curable by gene-therapy approaches. This bipartite vector, which allows cell-specific delivery of both the normal gene and shRNA to knockdown other genes in the pathway, represents a strategy that may help cure many more retinal degenerations. Degeneration of rod photoreceptors also affects approximately 9 million Americans with agerelated <u>macular degeneration</u>. Strategies to save photoreceptors in mouse models of RP may be applicable to that disease as well."

In spite of this high prevalence, the interplay between defective PDE metabolism and RP <u>pathogenesis</u> remains poorly understood. In several mouse models for RP, defects in the PDE6B enzyme result in increased levels of the signaling molecules cGMP (mediated by GUCY2E cyclase)



and Ca2+ (mediated by the CNGA1 channel).

Several aspects of the EBM report are innovative. It not only tackles the lack of functional PDE6 β (by augmenting function with conventional gene replacement), but simultaneously counteracts the central biochemical impact of that lost function by decreasing abnormally accumulated cGMP and Ca2+. Furthermore, they used a tissue-specific promoter to achieve cell-specific expression of the transduced genes, which is unusual for shRNA delivery.

The researchers at Columbia developed three different lentiviral vectors, each of them designed to deliver wild-type Pde6b cDNA and one of two shRNAs. One vector delivered the cDNA and GUCY2E shRNA to reduce cGMP levels; another vector delivered the wild-type cDNA and CNGA1 shRNA to reduce Ca2+ levels; the third delivered the cDNA and the Gucy2e shRNA with a tissue-specific promoter. The bipartite approach was conceived as a way to improve therapeutic efficacy over that of a single-therapy approach, which was tested in an earlier project from Dr. Tsang's lab. While the current project did not show improvement over their previous work, the researchers are optimistic that bipartite delivery may represent an important resource in future explorations of gene therapy in the eye and other tissues types.

Typical existing shRNA vector systems use the RNA polymerase III promoter, which is expressed in essentially all cell types, to drive expression of the transduced gene. However, expression of shRNA targeting GUCY2E in cone photoreceptors, which mediates color vision, would have unwanted and deleterious effects on vision. To achieve rod-specific expression of the shRNA, the researchers in this work embedded Gucy2e shRNA into the Pol II transcription unit of pre-miR34, which is expressed solely in rods. Similar methods can be used to target different tissues, so this method may have wide applicability.



The testing of <u>shRNA</u> therapeutic approaches in Pde6bH620Q mice should facilitate pre-clinical therapeutic evaluation of retinitis pigmentosa. Lessons learned from the proposed studies will eventually be translated into strategies for treatment trials in larger animal models of PDE6 β deficiency, such as Irish Setter dogs, before seeing application in human therapeutics.

Dr. Steve Goodman, Editor-in-Chief of Experimental Biology and Medicine said, "Researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have used a unique gene therapy approach to preserve photoreceptors and prolong functional vision in a <u>mouse</u> <u>model</u> of retinitis pigmentosa (RP). There work offers the promise of a future <u>gene therapy</u> cure for RP".

Provided by Society for Experimental Biology and Medicine

Citation: Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa (2011, September 30) retrieved 17 May 2024 from <u>https://medicalxpress.com/news/2011-09-cell-specific-mechanism-based-gene-therapy-approach.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.